# Clinical and Diagnostics Core

> **NIH NIH U19** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2023 · $229,019

## Abstract

Summary
Core 3: Clinical and Diagnostics Core Co-Directors: (Thompson and Kenyon)
The Core 3 will provide infrastructure and assays to support interdisciplinary discovery and translational research
objectives proposed in the Projects of this application. The Core 3 resources will support the investigation of
immune and metabolic correlates of the spectrum of disease encountered in coccidioidomycosis and treatment
outcomes (Project 3). Through the collection of CSF and peripheral blood samples, Core 3 will provide samples
for investigating host transcriptomic response in disseminated Coccidioides (Project 2). Core 3 will support an
evaluation of the diagnostic potential of Coccidioides antigens identified in Projects 1 and 2 and host biomarkers
identified in Project 2.
The Specific Aims of the Core 3 are the following: (1) To develop Coccidioides patient sample repositories that
link to clinical patient information through unique databases that support discovery and translational research on
coccidioidomycosis. (2) To increase coccidioidomycosis research collaborations by leveraging resources
available through the UC Davis Clinical and Translational Science Center (CTSC), West Coast Metabolomics
Center (WCMC) and other technology cores.
In summary, Core 3 will play a critical role in supporting the research investigations for the Projects 1, 2 and 3
by providing well defined clinical samples from patients with Coccidioides infection. In collaboration with the
CTSC, Core 3 will provide clinical (deidentified) data and serological findings from the Coccidioidomycosis
Diagnostic laboratory. Thus, Core 3 will serve as an important source of the clinical samples including serum,
CSF and PBMC samples. Additionally, Core 3 will evaluate the diagnostic potential of Coccidioides antigens
identified in the Projects 1 and 2 and host biomarkers identified in Project 2. If these candidates show promise,
further studies will be performed through the Diagnostic laboratory so that these reagents can be advanced to
the clinic.

## Key facts

- **NIH application ID:** 10540802
- **Project number:** 5U19AI166798-02
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** George Richard Thompson
- **Activity code:** U19 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2023
- **Award amount:** $229,019
- **Award type:** 5
- **Project period:** 2022-01-01 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10540802

## Citation

> US National Institutes of Health, RePORTER application 10540802, Clinical and Diagnostics Core (5U19AI166798-02). Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/grant/nih/10540802. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*